Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) AI Stock Analysis

2 Followers

Jagsonpal Pharmaceuticals Ltd.

(NSE:JAGSNPHARM)

Select Model

Rating:66Neutral

Price Target:INR 231.00▲(6.77% Upside)

Action:downgraded

Date:11/07/26

Strong financial performance is the primary driver supporting the score, while technical indicators show mild weakness and valuation appears somewhat elevated.

Positive Factors

Low LeverageMinimal leverage gives Jagsonpal substantial financial flexibility and reduces the burden of interest and refinancing obligations. This supports resilience through weaker operating periods while preserving capacity to fund product development, distribution expansion, or other growth initiatives internally.

Negative Factors

Earnings DeclineThe decline in net income despite stronger revenue shows that top-line expansion has not consistently translated into bottom-line growth. Persistent earnings conversion pressure could limit retained capital, weaken returns to shareholders, and make future profitability less predictable.

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 11.37B
Dividend Yield: 1.84%
Average Volume (3M): 12.98K
Price to Earnings (P/E): 31.9
Beta (1Y): 0.80
Revenue Growth: 11.71%
EPS Growth: -26.92%
Country: India
Employees: 1,297
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Jagsonpal Pharmaceuticals Limited, an Indian company founded in 1964 and based in New Delhi, specializes in the development and manufacturing of both bulk active pharmaceutical ingredients and diverse medicinal formulations. Its product portfolio spa...

How the Company Makes Money

Jagsonpal Pharmaceuticals primarily makes money by selling pharmaceutical formulations (finished dosage medicines) in the Indian market. Revenue is generated through (1) domestic sales of branded formulations to channel partners such as stockists/dis...

Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview

Summary

Solid financial health driven by a strong balance sheet with low debt-to-equity under 0.06 and growing assets, improving profitability with net margins up to 21%, and positive operating cash flows despite revenue volatility.

Income Statement

75Positive

Balance Sheet

85Very Positive

Cash Flow

70Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	2.94B	2.87B	2.69B	2.09B	2.37B	2.18B
Gross Profit	1.63B	1.83B	1.72B	652.59M	1.44B	1.28B
EBITDA	681.92M	679.90M	510.71M	323.46M	362.61M	284.29M
Net Income	454.76M	430.82M	553.61M	224.63M	267.21M	188.55M
Balance Sheet
Total Assets	0	3.17B	2.78B	2.17B	1.95B	1.68B
Cash, Cash Equivalents and Short-Term Investments	1.06B	1.06B	1.29B	1.48B	1.15B	472.77M
Total Debt	0	81.65M	92.39M	89.41M	60.01M	52.47M
Total Liabilities	-2.76B	405.05M	383.10M	296.76M	360.56M	375.99M
Stockholders Equity	2.76B	2.76B	2.40B	1.87B	1.59B	1.31B
Cash Flow
Free Cash Flow	245.77M	466.64M	549.52M	349.18M	463.37M	51.31M
Operating Cash Flow	246.75M	468.12M	553.00M	351.66M	466.54M	55.98M
Investing Cash Flow	-82.07M	-356.49M	-451.47M	-245.48M	-576.71M	-257.79M
Financing Cash Flow	-148.90M	-121.49M	-116.98M	-89.11M	-4.57M	-175.52M

Jagsonpal Pharmaceuticals Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price216.35

Price Trends

50DMA227.55Negative

100DMA227.02Negative

200DMA206.65Positive

Market Momentum

MACD-2.87Negative

RSI44.34Neutral

STOCH24.72Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Negative. The current price of 216.35 is below the 20-day moving average (MA) of 218.94, below the 50-day MA of 227.55, and above the 200-day MA of 206.65, indicating a neutral trend. The MACD of -2.87 indicates Negative momentum. The RSI at 44.34 is Neutral, neither overbought nor oversold. The STOCH value of 24.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JAGSNPHARM.

Jagsonpal Pharmaceuticals Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:JAGSNPHARM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:SYNCOMF	79Outperform	INR 18.85B	22.38	―	0.49%	0.44%	48.60%
IN:VENUSREM	72Outperform	INR 19.37B	15.86	―	0.70%	20.22%	73.03%
IN:LINCOLN	67Neutral	INR 10.43B	10.80	―	0.35%	14.25%	21.11%
IN:JAGSNPHARM	66Neutral	INR 14.39B	31.89	―	1.84%	11.71%	-26.92%
IN:SAKAR	66Neutral	INR 22.58B	55.82	―	―	47.99%	117.99%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:INDSWFTLAB	51Neutral	INR 30.39B	37.21	―	―	66.39%	-72.31%

* General Sector Average

Performance Comparison

IN:JAGSNPHARM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:JAGSNPHARM	Jagsonpal Pharmaceuticals Ltd.	216.35	9.27	4.48%
IN:INDSWFTLAB	Ind-Swift Laboratories Ltd.	362.20	258.30	248.60%
IN:LINCOLN	Lincoln Pharmaceuticals Ltd	521.10	-2.56	-0.49%
IN:SAKAR	Sakar Healthcare Ltd	1075.70	680.75	172.36%
IN:SYNCOMF	Syncom Formulation (India) Ltd.	20.37	3.88	23.54%
IN:VENUSREM	Venus Remedies Limited	1434.45	868.55	153.48%

Jagsonpal Pharmaceuticals Ltd. Corporate Events

Jagsonpal Pharma Sets Virtual AGM and Dividend Record Date for September 2026

Aug 27, 2026

Jagsonpal Pharmaceuticals Limited has scheduled its 47th Annual General Meeting for September 18, 2026, to be conducted via video conferencing and other audio-visual means in line with regulatory guidance. The company has circulated the AGM notice an...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026

Jagsonpal Pharmaceuticals Ltd. AI Stock Analysis